Please assess the completion status of the following clinical trial:

Trial Title: Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (Age ≧ 20) who received the first allo-HSCT are eligible;~* Patients with underlying disease of acute leukemia in morphological remission, or myelodysplastic syndrome;~* Received allo-HSCT with HLA-matched sibling or unrelated donors (at least 8/8 match for HLA-A/B/C/DR);~* Evidence of post-transplantation neutrophil engraftment: absolute neutrophil count \> 500/mm3 for at least 3 consecutive days;~* No detectable CMV infection before study enrollment: negative plasma CMV DNA surveillance within passing 2 weeks;~* No previous post-transplantation anti-CMV therapy and no planned prophylactic anti-CMV therapy;~* The patients has the ability to swallow tablets~Exclusion Criteria:~* They have renal insufficiency: serum creatinine \> 2.5 mg/dL;~* They have hepatic dysfunction: serum alanine or aspartate aminotransferase levels of \> 5 times the upper limit of the normal range or a serum total bilirubin of \> 3 mg/dL;~* Patients with history of HIV infection;~* Unstable post-BMT condition or other medical condition deemed not appropriate to be included to this study as judged by investigator;~* Life expectancy less than 3 months;~* Unwillingness or unable to give consent;~* Patients with diseases that are positive for t(9;22) or BCR-ABL fusion gene.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.

Based on this trial design, predict the completion outcome and termination type (if applicable).